Burn injuries are a devastating critical care problem. In children, burns continue to be a major epidemiologic problem around the globe resulting in significant morbidity and death. Apparently, treating these burn injuries in children and adults remains similar, but there are significant physiological and psychological differences. The dermal layer of the skin is generally thinner in neonates, infants, and children than in adults. Enhanced evaporative loss and need for isotonic fluids increases the risk of hypothermia in the pediatric population. The pain management of the children with major burns challenges the skills of the personnel of every unit. Managing these wounds requires intensive therapeutic treatment for multi-organ dysfunction, and surgical treatment to prevent sepsis and other complications that further delay wound closure. Alternatives to the practice of donor site harvest and autografting for the treatment of severe burns and other complex skin defects are urgently needed for both adult and pediatric populations. This review article focuses on thermal burn pathophysiology and pain management and provides an overview of currently approved products used for the treatment of pediatric burn wounds. A new promising approach has been presented as a first-line therapy in the treatment of burns to reduce surgical autografting in pediatric patients.

9Burns is a pervasive and oppressive basic care issue. In children, burn injuries are a major reason 10 for bleakness and mortality. The quirks in the physiology of liquid and electrolyte taking care of, 11 the vital necessity and the distinctions in the different body extends in children direct that the 12 pediatric wounds administration ought to be brought with an alternate point of view than for

Chronic non-healing ulcers are a significant medical problem and the incidence of these wounds is expected to increase as the United States population ages. It was projected that approximately 1,400,000 diabetics i country alone would suffer from Diabetic foot ulcer (DFU) in 2015. The three major challenges in the medical management of DFU are 1) reduction of microbial infection both directly and through enhancement of a productive immune response, 2) restoration of a constructive wound healing microenvironment, and 3) induction of sufficient revascularization. A recent European study showed that approximately 28% of patients with infected DFU required amputations. Although the data are challenging to interpret due to the wide range of disease severities included in the analyses, standard therapies only cure approximately 30% of DFU after 20 weeks and at best advanced modality therapies achieve ~56% healing at 12 weeks. The increasing prevalence of chronic non-healing ulcers poses significant clinical challenges to wound care, often requiring the use of potent antibiotics with undesirable side effects on wound healing. However, no current product addresses both infection and closure of chronic non ulcers. There is an unmet medical need for alternative products assessed by randomized, controlled trials with well-defined and controlled manufacturing processes for the treatment of chronic cutaneous ulcers. The present review emphasizes on development of the n generation of therapeutic skin substitutes which promote wound closure.